Vascular Biogenics Ltd. (VBLT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
VBLT Chart
Vascular Biogenics Ltd. Dividends
Vascular Biogenics Ltd. Earnings
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2024 Date | | - Cons. EPS | - EPS |
| 12 Mar 2024 Date | | - Cons. EPS | - EPS |
| 13 Nov 2023 Date | | - Cons. EPS | - EPS |
| 10 Nov 2016 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2024 Date | | - Cons. EPS | - EPS |
| 12 Mar 2024 Date | | - Cons. EPS | - EPS |
| 13 Nov 2023 Date | | - Cons. EPS | - EPS |
| 10 Nov 2016 Date | | - Cons. EPS | - EPS |
Vascular Biogenics Ltd. (VBLT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Vascular Biogenics Ltd. ever had a stock split?
Vascular Biogenics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Prof. Dror Harats M.D. CEO | NASDAQ (CM) Exchange | M96883109 Cusip |
| IL Country | 7 Employees | - Last Dividend | 17 Oct 2023 Last Split | - IPO Date |
Overview
Vascular Biogenics Ltd. operates as a clinical-stage biopharmaceutical entity engaged in the development of innovative therapeutics for the management of cancer and immune-inflammatory conditions. Based in Modi'in, Israel, with operations extending to the United States, the company is renowned for pioneering gene-based and antibody-based technologies aimed at targeting newly formed blood vessels and inhibiting monocyte migration. This strategic focus is poised to revolutionize treatment modalities in oncology and inflammation. Established originally as Medicard Ltd., the organization rebranded to Vascular Biogenics Ltd. in January 2003, marking a significant pivot in its mission and scope since its inception in 2000.
Products and Services
- VB-111
- VB-601
- VB-611
A flagship gene-based biologic therapy developed by Vascular Biogenics, VB-111 is currently in the limelight for its Phase III clinical trials targeting recurrent platinum-resistant ovarian cancer. Besides, VB-111 is under Phase II clinical scrutiny for recurrent glioblastoma and colorectal cancer, having successfully concluded Phase II trials for thyroid cancer. VB-111's mechanism, leveraging the vascular targeting system technology, focuses on destroying cancer through the eradication of its blood supply, distinguished for its ingenuity in selective targeting.
VB-601 is an advanced therapy candidate moving through Vascular Biogenics' pipeline with a spotlight on immune-inflammatory diseases. This antibody-based therapy, benefiting from the monocyte targeting technology, demonstrates a novel approach to specifically inhibiting monocyte migration. VB-601 holds the potential to offer relief for patients suffering from various inflammatory conditions, hinting at an expansive application scope.
Designed to combat solid tumors, VB-611 emerges as another promising therapy from Vascular Biogenics' innovative roster. Though specifics on its clinical phase and detailed mechanism are succinct, VB-611's development is indicative of the company's commitment to leveraging its proprietary technologies for extending treatment possibilities in oncology.
Contact Information
